These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28583911)

  • 1. First Tissue-Agnostic Drug Approval Issued.
    Cancer Discov; 2017 Jul; 7(7):656. PubMed ID: 28583911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision medicine becomes reality-tumor type-agnostic therapy.
    Yan L; Zhang W
    Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
    Lemery S; Keegan P; Pazdur R
    N Engl J Med; 2017 Oct; 377(15):1409-1412. PubMed ID: 29020592
    [No Abstract]   [Full Text] [Related]  

  • 4. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
    Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
    J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
    Marcus L; Lemery SJ; Keegan P; Pazdur R
    Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three Drugs Approved for Urothelial Carcinoma by FDA.
    Cancer Discov; 2017 Jul; 7(7):659-660. PubMed ID: 28546286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Making precision oncology the standard of care.
    The Lancet Oncology
    Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
    Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy.
    Garber K
    Nat Biotechnol; 2017 Apr; 35(4):297-298. PubMed ID: 28398313
    [No Abstract]   [Full Text] [Related]  

  • 12. When biomarkers define a drug indication.
    Jørgensen JT
    Expert Rev Mol Diagn; 2018 Apr; 18(4):315-317. PubMed ID: 29333885
    [No Abstract]   [Full Text] [Related]  

  • 13. Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors.
    Akagi K; Oki E; Taniguchi H; Nakatani K; Aoki D; Kuwata T; Yoshino T
    Cancer Sci; 2021 Mar; 112(3):1105-1113. PubMed ID: 33403729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2015 Jan; 51(1):7-20. PubMed ID: 25685857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed death 1 immune checkpoint inhibitors.
    Trivedi MS; Hoffner B; Winkelmann JL; Abbott ME; Hamid O; Carvajal RD
    Clin Adv Hematol Oncol; 2015 Dec; 13(12):858-68. PubMed ID: 27058852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dostarlimab: First Approval.
    Markham A
    Drugs; 2021 Jul; 81(10):1213-1219. PubMed ID: 34106455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
    Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.
    Chen KH; Yuan CT; Tseng LH; Shun CT; Yeh KH
    J Hematol Oncol; 2016 Mar; 9():29. PubMed ID: 27012666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.